Establishment and characterization of mouse metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma organoids
November 10, 2024 / MASH-related HCC Organoids / Lenvatinidb Resistance / Mult-biotics Therapy
This study established MASH-related hepatocellular carcinoma (HCC) organoids to assess drug responses, revealing that multi-biotics enhance Lenvatinib sensitivity. Transcriptomic analysis highlighted KRAS signaling and inflammation as key pathways in developing Lenvatinib resistance.
Disentangling the body mass index, metabolic health and aging connection
November 8, 2024 / Body Mass Index / Aging / Metabolic Health Impact / BMI / Mortality Risk / Metabolic Disorders
This study reveals that both high and low BMI, alongside poor metabolic health, are linked to accelerated biological aging and mortality. Integrating metabolic health in assessments may better address health risks across BMI levels, especially in older adults.
As research continues, compounded semaglutide may play an increasingly important role in treating obesity and related metabolic disorders.
November 8, 2024 / Compounded Semaglutide Benefits / GLP-1 Receptor / Weight Loss / Metabolic Health / Obesity Treatment / Type 2 Diabetes
Compounded semaglutide, a GLP-1 receptor agonist, effectively reduces appetite, controls blood sugar, and enhances metabolic health, aiding in weight loss and type 2 diabetes management. Studies show significant benefits, though gastrointestinal side effects are common.
People who drink ingredient every day lose 18lbs in three months
November 8, 2024 / Apple Cider Vinegar / Weight Loss / Metabolic Benefits / Obesity Management / BMI / Blood Glucose Reduction
A study found daily apple cider vinegar intake aids weight loss, reducing BMI, blood glucose, and cholesterol in obese individuals. These findings suggest potential metabolic benefits, though further research is needed to confirm long-term effects.
Exploring the protective effects of HSD17B13 in hepatic steatosis
November 8, 2024 / Liver Disease / Hepatic Steatosis Treatment / MASH / ALD Genetic Protection / Liver Fibrosis
The HSD17B13 gene, particularly its rs72613567 variant, shows protective effects against liver disease progression, including reduced risk of fibrosis and hepatocellular carcinoma in MASH and ALD. Targeting HSD17B13 offers potential for new liver disease therapies.
Combined lifestyle factors and metabolic syndrome risk: a systematic review and meta-analysis
November 8, 2024 / Metabolic Syndrome Prevention / Healthy Lifestyle Impact / Diet and Metabolic Syndrome Risk / Chronic Disease
This meta-analysis found that adherence to healthy lifestyle factors significantly reduces metabolic syndrome risk, with the healthiest lifestyles linked to a 43% lower risk. Physical activity, diet, and smoking were key factors influencing metabolic syndrome outcomes.
Mediterranean diet may reduce type-2 diabetes risk in fatty liver patients
November 8, 2024 / Mediterranean Diet / Diabetes Prevention / MAFLD / Type-2 Diabetes Risk / Liver Health / Metabolic Liver Disease
Mediterranean diet adherence may significantly reduce type-2 diabetes risk in patients with metabolic dysfunction-associated fatty liver disease (MAFLD), likely due to its anti-inflammatory and antioxidant benefits, which improve both liver health and metabolic outcomes.
High phthalate, plasticizer metabolite concentrations tied to metabolic syndrome in young
November 7, 2024 / Phthalates / Metabolic Syndrome / Plasticizer Exposure in Youth / Adolescent Metabolic Health Risk
Elevated phthalate and plasticizer metabolite levels are linked to increased metabolic syndrome risk in U.S. adolescents and young adults. Findings suggest potential public health implications, emphasizing further research on plasticizer exposure and long-term metabolic health.
Metabolic surgery cuts diuretic dependence in heart failure patients
November 7, 2024 /Metabolic Surgery Heart Failure Benefits / Diuretic Reduction Post-surgery / Obesity / Heart Failure Treatment / Metabolic Surgery Outcomes / Heart Failure / Weight Loss Surgery
Metabolic surgery in heart failure patients led to a 65% reduction in diuretic use and significant weight loss, highlighting its benefits for obesity-related heart failure management and quality of life improvement.
Zepbound’s Weight Loss, Cardiometabolic Benefits Hold Up at 3 Years
November 7, 2024 / Tirzepatide Weight Loss Results / Cardiometabolic Benefits / GLP-1 / Obesity
Tirzepatide led to substantial, sustained weight loss (up to 22.9%) and cardiometabolic improvements over three years in patients with obesity or overweight. Cardiometabolic benefits included improved glucose, lipids, and blood pressure, though weight regain occurred after discontinuation.
Metabolic surgery may help reduce heart failure-related risk factors
November 7, 2024 / Metabolic Surgery / Heart Failure Benefits / Biuretic Reduction Post-Surgery / Obesity / Heart Failure Treatment / Weight Loss
Metabolic surgery in heart failure patients led to significant weight loss and a 65% reduction in diuretic use over two years, suggesting substantial benefits for obesity-related heart failure management and reduced dependency on medication.
Liver-brain connection revealed as key to eating habits and metabolism
November 7, 2024 / Liver-brain Connection / Metabolism / Circadian Rhythm / Eating Habits / REV-ERB Genes and Metabolism
A Penn Medicine study reveals that liver-brain communication, via the vagus nerve, regulates eating aligned with circadian rhythms. Disrupted signals can lead to overeating, suggesting potential therapies for metabolic issues in shift workers.
Disruptions in liver and brain clocks contribute to unhealthy eating patterns
November 7, 2024 / Circadian Rhythm / Obesity / Liver-Brain Block Connection / Hepatic Vagal Nerve / Metabolism
Disruptions between liver and brain circadian clocks, communicated via the hepatic vagal nerve, can lead to unhealthy eating and weight gain. Targeting this liver-brain circuit may offer therapeutic strategies for obesity related to circadian misalignment.
Weight-Loss Surgery Down 25 Percent as Anti-Obesity Drug Use Soars
November 7, 2024 / GLP-1 RAs vs. Bariatric Surgery / Obesity Treatment Trends / Anti-obesity Treatment Trends / Bariatric Surgery Decline
As GLP-1 RA usage for obesity doubled, bariatric surgery declined by 25.6% from 2022 to 2023. This shift highlights the need to evaluate long-term outcomes and maintain broad access to both pharmacologic and surgical obesity treatments.
Incretin-based therapies for the treatment of obesity-related diseases
November 6, 2024 / Incretin-based Obesity Therapies / GLP-1 Receptor Agonists / Weight Loss / Cardiovascular Benefits / Incretin Therapy / Tirzepatide / Semaglutide Efficacy
Incretin-based therapies (like liraglutide, semaglutide, and tirzepatide) are increasingly effective for obesity management, reducing body weight and obesity-related comorbidities such as T2D and cardiovascular disease. New drugs in this class show promise in both weight loss and metabolic improvement.
Why Digital Twin Technology Could Help Maximize GLP-1 Efficacy
November 5, 2024 / Digital Twin Technology / GLP-1 / Personalized Metabolic Health / Twin Health Digital Twin Model / Chronic Disease Management Technology
Digital twin technology, integrating data from various health monitors, enhances GLP-1 efficacy by personalizing metabolic interventions. Twin Health’s model supports comprehensive metabolic health improvements, addressing lifestyle factors impacting chronic disease outcomes.
Scientists identify immune molecule that keeps metabolism in tune and on time
November 5, 2024 / IL-17A / Metabolism / Immune System / Circadian Rhythm / Obesity Therapy Immune Targeting / Metabolic Disorders
Research identifies IL-17A, an immune molecule in fat tissue, as a key regulator of fat storage and circadian metabolic rhythm. Targeting IL-17A may offer new therapies for obesity, metabolic disorders, and issues arising from circadian disruption.
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
November 4, 2024 / Ascendis Novo Nordisk Collaboration / TransCon Technology / GLP-1 Therapy / Metabolic Disease Treatments / Cardiometabolic Innoation
Ascendis Pharma has licensed its TransCon technology to Novo Nordisk for developing GLP-1 and cardiometabolic treatments, potentially reducing dosing frequency. Ascendis will receive milestone payments and royalties, while Novo Nordisk handles commercialization.
Meta-analysis links meal timing to modest weight loss
November 4, 2024 / Meal Timing / Weight Loss / Time-restricted Eating Benefits / Circadian Rhythm Diet Strategies / Obesity / Metabolic Health
A meta-analysis from Bond University links meal timing strategies, like time-restricted eating and reduced meal frequency, to modest weight loss and minor metabolic improvements. However, study biases and limited clinical significance highlight the need for further research.
Ketogenic diets could be better for menstrual health, period
November 4, 2024 / Ketogenic Diet / Menstrual Health / Insulin Sensitivity in PCOS / Diet Impacts on Reproductive Health / Menstrual Changes with Ketosis
A study found ketogenic diets (KD) increased menstrual frequency and intensity in overweight women, unlike low-fat diets (LFD). KD participants also showed significant weight loss, reduced insulin, and improved insulin sensitivity, suggesting unique metabolic effects on menstrual health.